Su1857 SAFETY OF TOFACITINIB ON POSTOPERATIVE OUTCOMES AFTER SUBTOTAL COLECTOMY IN ULCERATIVE COLITIS

Kani, Haluk Tarık; Esen, Eren; Chang, Shannon; Hudesman, David; Remzi, Feza H.; Axelrad, Jordan E.

doi:10.1016/s0016-5085(20)32384-2

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postoperative outcomes were reported in 3 studies 32,41,46. Rates of any 30-day complications were 20% to 46%, rates of surgical site infections were 5.7% to 9.1%, and reoperation rates were 0% to 9%.…”

Section: Resultsmentioning

confidence: 99%

“…After excluding 32 studies for reasons documented in Figure 1, 24 articles representing 26 independent studies were included in our analysis. 7,[10][11][12][13][14][15][16][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46] An RCT study design was used in 4 studies, 7,34 and the rest were observational designs. Twenty studies reported efficacy outcomes 7,[10][11][12][13][14][15][16]31,[33][34][35][36][37][38][39][40]42,44,45 and 25 studies reported safety outcomes.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty studies reported efficacy outcomes 7,[10][11][12][13][14][15][16]31,[33][34][35][36][37][38][39][40]42,44,45 and 25 studies reported safety outcomes. 7,[10][11][12][13][14][15][16][31][32][33][34][35][36][38][39][40][41][42][43][44][45][46] Study characteristics are outlined in Table 1. Summary of efficacy and safety outcomes among included studies are reported in the Supplement (Tables 1, 2, Supplemental Digital Content 1, http://links.lww.com/JCG/A771).…”

Section: Resultsmentioning

confidence: 99%

“…Postoperative outcomes were reported in 3 studies. 32,41,46 Rates of any 30-day complications were 20% to 46%, rates of surgical site infections were 5.7% to 9.1%, and reoperation rates were 0% to 9%. In the study by Lightner et al 46 which reported 90-day outcomes, 7 patients (13.2%) developed VTE at the following sites: portomesenteric venous thrombosis (n = 4), internal iliac vein thrombosis (n = 2), and PE (n = 1).…”

Section: Postoperative Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness and Safety of Tofacitinib for Ulcerative Colitis

Taneja¹,

El-Dallal

Haq

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Background: The objective of our systematic review and meta-analysis was to evaluate the effectiveness and safety of tofacitinib in the treatment of moderate-severe ulcerative colitis (UC). Methods: We searched Medline, Embase, Web of Science, and Cochrane Central to identify articles and abstracts reporting efficacy or safety data on tofacitinib use in UC. Primary outcome assessed was remission. Secondary outcomes included clinical response, steroid free remission, and adverse events (AEs). Results: A total of 26 studies were included. The rates of remission were 29.81% [95% confidence interval (CI): 22.37%-37.25%, I 2: 90%] at week 8, 32.27% (95% CI: 27.67%-36.88%, I 2: 42%) at 6 months and 38.03% (95% CI: 33.59%-42.48%, I 2: 0%) at 1-year. Clinical response rates were 59.41% (95% CI: 55.03%-63.94%, I 2: 61%) at week 8, 48.99% (95% CI: 36.92%-61.06%, I 2: 91%) at 6 months and 50.87% (95% CI: 42.16%-59.58%, I 2: 67%) at 1-year. Odds ratio of clinical response at week 8 in biologic naive versus biologic experienced patients was 1.59 (95% CI: 0.54-4.63). Pooled incidence rate for serious infections, major adverse cardiovascular events, and nonmelanotic squamous cell malignancies across all doses was 4.41 per 100-patient years (PYs) (95% CI: 2.32-8.38 per 100-PY, I 2: 78%), 0.91 per 100-PY (95% CI: 0.43-1.93 per 100-PY, I 2: 37%) and 0.91 per 100-PY (95% CI: 0.61-1.34 per 100-PY, I 2: 0%), respectively. Higher dose was associated with an increased frequency of AEs. Conclusions: While the overall efficacy and safety of tofacitinib in moderate-severe UC is consistent with clinical trial data, the dose dependent increase in AEs highlights the significance of early dose de-escalation. Rate of clinical response after tofacitinb induction was similar in biologic naive and biologic experienced patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Postoperative Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness and Safety of Tofacitinib for Ulcerative Colitis

Taneja¹,

El-Dallal

Haq

et al. 2021

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…68 Furthermore, Kani et al concluded that preoperative tofacitinib exposure was not associated with an increased risk of 30-day postsurgical outcomes when compared with preoperative exposure to other biologics. 69…”

Section: Post-operative Surgical Outcomesmentioning

confidence: 99%

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

Liu¹,

Aslam²,

Nigam³

et al. 2022

DIC

View full text Add to dashboard Cite

Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn's disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the National Institute for Health and Care Excellence (NICE) for use in moderately-to-severely active UC after intolerance, inadequate response, or loss of response to conventional treatment or biologic therapy. The pivotal OCTAVE studies demonstrated the efficacy and safety of tofacitinib for the induction and maintenance of remission in UC. A growing body of evidence from real-world data supports the positive clinical and endoscopic benefits observed with tofacitinib treatment in the OCTAVE trials. This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. We explore evolving treatment paradigms, including the use of tofacitinib in the COVID-19 era, pregnancy and extraintestinal manifestations, as well as the emerging concept of combining tofacitinib with biological therapy. We will also present a brief overview of the next generation of JAK inhibitors in the pipeline.

show abstract

Su1857 SAFETY OF TOFACITINIB ON POSTOPERATIVE OUTCOMES AFTER SUBTOTAL COLECTOMY IN ULCERATIVE COLITIS

Cited by 2 publications

References 0 publications

Effectiveness and Safety of Tofacitinib for Ulcerative Colitis

Effectiveness and Safety of Tofacitinib for Ulcerative Colitis

Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going

Contact Info

Product

Resources

About